Omalizumab therapy does not appear to elevate the risk of coronavirus infection and can be safely used in people with chronic spontaneous urticaria.

A descriptive cross-sectional study was carried out for assessing the prevalence of SARS-CoV-2-related symptoms and COVID-19 real-time polymerase chain reaction (RT-PCR) positivity in urticaria patients regarding age, sex, presence of other comorbidities, disease duration, treatment duration, and kind of therapy administered for urticaria.

The study recruited 233 participants (160 females, 73 males, mean age 44.76 ± 14.16 years) having urticaria. Participants were segregated to receive only omalizumab, only oral antihistamines, and omalizumab along with oral antihistamines.

With the aid of a telephone survey; demographical data, therapy given for urticaria, presence of coronavirus-linked symptoms, history of close contact with a coronavirus-infected person, and COVID-19 RT-PCR results were assessed and verified from the medical data records.

Notably, 125/233 participants were found to have symptoms linked with COVID-19 infection. RT-PCR testing was carried out in 156 participants. Of 156 people with the RT-PCR test, 15 people were reported to be positive.

In patients diagnosed with chronic spontaneous urticaria, no profound association was witnessed between SARS-CoV-2 RT-PCR positivity and the kind of therapy given for chronic spontaneous urticaria. Omalizumab appears to be safe in the era of coronavirus disease.